QUICKLINKS AND VIEW OPITONS
Acomplia’s (rimonabant) blocks cannabinoid receptor: What are the implications?
Thursday, June 14, 2007 2:21 am Email this article
Acomplia (rimonabant) reduces appetite by blocking a receptor called the cannabinoid-1 receptor. Stimulation of these and other receptors help to protect against anxiety, phobias, depression and posttraumatic stress disorders. Stimulation of these receptors may also protect against neurotoxicity and some forms of epilepsy. Therefore, drugs that block this receptor, such as Acomplia (rimonabant), should not be used carefully and monitored closely in patients with anxiety, depression, epilepsy and neurodegenerative disorders according to the U.S. Food and Drug Administration (FDA) briefing document about the drug.
Articles on the same subject can be found here:
Please feel free to share your comments about this article.
© Copyright 2003-2017 - Larry Hobbs - All Rights Reserved.